Source-grounded facts extracted from Regen BioPharma Inc's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Regen BioPharma Inc issued 77,849,847 common shares of common stock for satisfaction of $53,474 of principal convertible indebtedness, $4,249 of accrued interest on convertible indebtedness and $11,000 in incurred fees.
“Between February 4, 2026 and February 27, 2026 the Company issued 77,849,847 common shares (“Shares”) in satisfaction of $53,474 of principal convertible indebtedness, $4,249 of accrued interest on convertible indebtedness and $11,000 in incurred fees.”
Regen BioPharma Inc issued 11,111,111 common shares of common stock for $50,000.
“On January 30, 2026 the Company issued 11,111,111 common shares (“Shares”) for consideration consisting of $50,000.”
Regen BioPharma Inc issued 5,302,732 common shares of common stock for $12,000 of principal convertible indebtedness and $1,000 of accrued interest.
“On January 29, 2026 the Company issued 5,302,732 common shares (“Shares”) in satisfaction of $12,000 of principal convertible indebtedness and $1,000 of accrued interest on convertible indebtedness.”
Regen BioPharma Inc issued 5,000,000 common shares of common stock for $11,449 of principal convertible indebtedness and $8,101 of accrued interest.
“On January 15, 2026 the Company issued 5,000,000 common shares (“Shares”) in satisfaction of $11,449 of principal convertible indebtedness and $8,101 of accrued interest on convertible indebtedness.”
Regen BioPharma Inc reported that prior financial statements should not be relied upon.
“ALANCE SHEETS Originally Presented Restated As of September 30, 2024 Adjustments As of September 30, 2024 ASSETS Current Assets Cash $ 716 - $ 716 Accounts Receivable, Related Party 94,873 - 94,873 Prepaid Assets 64,289 (16,527 ) 47,762 Total Current Assets 159,878 (16,527 ) 143,351 Other Assets Investment Securities, Related Party 17,733 - 17,733 Total Other Assets 17,733 - 17,733 TOTAL ASSETS $ 177,611 (16,527 ) $ 161,084 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities: Accounts payable 29,669 - 29,669 Accrued Expenses 1,664,827 - 1,664,827 Notes Payable 293,819 - 293,819 Unearned Income 1,465,171 - 1,465,171 Unearned Income ( Related Party) - - - Derivative Liability 1,397,274 6,816 1,404,090 Convertible Notes Payable Less unamortized discount 499,880 - 499,880 Convertible Notes Payable, Related Parties Less unamortized discount - - - Other Current Liabilities 21,000 - 21”
Regen BioPharma Inc dismissed Bush and Associates CPA LLC as its auditor.
“On March 31, 2025 the Board of Directors of the Registrant, acting as the Registrant's Audit Committee, approved the dismissal of Bush and Associates CPA LLC ("Bush') as the Registrant's independent registered public accounting firm effective immediately”
Regen BioPharma Inc engaged BCRG Group as its auditor.
“On March 31, 2025 the Board of Directors of Regen Biopharma, Inc. (the "Registrant"), acting as the Registrant's Audit Committee, approved the engagement of BCRG Group ("BCRG") as its independent auditor.”
Regen BioPharma Inc dismissed BF Borgers CPA PC as its auditor.
“On May 10, 2024 the Board of Directors of Regen Biopharma, Inc. (the “Company”) approved the dismissal; of BF Borgers CPA PC as the Company’s independent registered public accounting firm, effective immediately”
Regen BioPharma Inc entered into Registration Rights Agreement with Coventry (effective 2023-09-12).
“In connection with the Equity Line Agreement the Company also entered into a Registration Rights Agreement, dated September 12, 2023 with Coventry (the “Registration Rights Agreement”), pursuant to which the Company agreed to register for resale under the Securities Act of 1933 shares issuable in accordance with the Equity Line Agreement”
Regen BioPharma Inc entered into common stock purchase agreement with Coventry valued at up to Ten Million Dollars ($10,000,000) (effective 2023-09-12).
“On September 12, 2023 the Company entered into a common stock purchase agreement (the “Equity Line Agreement”) with Coventry providing for an equity financing facility (the “Equity Line”).”
Regen BioPharma Inc entered into Purchase Agreement with Coventry Enterprises, LLC valued at $175,000 (effective 2023-09-12).
“Effective September 12, 2023 Regen Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with Coventry Enterprises, LLC (“Coventry”), pursuant to which Coventry Enterprises purchased a 10% unsecured promissory Note (the “Note”) from the Company in the principal amount of $175,000”
Regen BioPharma Inc: Certificate of Change authorizing 1-for-1500 reverse stock split of all issued series of stock effective March 6, 2023 (effective 2023-03-06).
“A Certificate of Change authorizing 1 for 1500 reverse stock split of all issued series of stock.”
Regen BioPharma Inc: Amendment to Certificate of Designations reducing Series NC Preferred Stock votes per share to 334 as of March 6, 2023 (effective 2023-03-06).
“An amendment to the Certificate of Designations of the Company’s Series NC Preferred Stock reducing that number of votes per share of Series NC Preferred stock to three hundred and thirty four votes per share as of March 6, 2023”
Regen BioPharma Inc: Amendment to Certificate of Designations reducing Series AA Preferred Stock votes per share to seven as of March 6, 2023 (effective 2023-03-06).
“An amendment to the Certificate of Designations of the Company’s Series AA Preferred Stock reducing that number of votes per share of Series AA Preferred stock to seven votes per share as of March 6, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.